Sirolimus in renal transplant recipients with malignancies in Germany

Naik MG, Arns W, Budde K, Diekmann F, Eitner F, Gwinner W, Heyne N, Jurgensen JS, Morath C, Riester U, Heller KM, Fischereder M (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Clinical Kidney Journal Oxford University Press

Book Volume: 14

Pages Range: 2047-2058

Journal Issue: 9

DOI: 10.1093/ckj/sfaa262

Abstract

Background. Renal transplant recipients have an increased cancer risk. The mammalian target of rapamycin inhibitor sirolimus (SRL) has immunosuppressive and antitumour activities but knowledge about its use in recipients with cancer is limited.

Involved external institutions

Ruprecht-Karls-Universität Heidelberg

Germany (DE) Charité - Universitätsmedizin Berlin

Germany (DE) Eberhard Karls Universität Tübingen

Germany (DE) Klinikum der Universität München (Großhadern und Innenstadt)

Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School

Germany (DE) Pfizer Pharma GmbH

Germany (DE) Bayer AG

Germany (DE) Hospital Clínic de Barcelona

Spain (ES)

How to cite

APA:

Naik, M.G., Arns, W., Budde, K., Diekmann, F., Eitner, F., Gwinner, W.,... Fischereder, M. (2021). Sirolimus in renal transplant recipients with malignancies in Germany. Clinical Kidney Journal, 14(9), 2047-2058. https://doi.org/10.1093/ckj/sfaa262

MLA:

Naik, Marcel G., et al. "Sirolimus in renal transplant recipients with malignancies in Germany." Clinical Kidney Journal 14.9 (2021): 2047-2058.

BibTeX: Download